OBJECTIVE: To provide updated estimates of the prevalence and clinical impact of human immunodeficiency virus-associated sensory neuropathy (HIV-SN) and neuropathic pain due to HIV-SN in the combination antiretroviral therapy (CART) era. DESIGN: Prospective, cross-sectional analysis. Clinical correlates for HIV-SN and neuropathic pain, including age, exposure to CART, CD4 levels, plasma viral load, hepatitis C virus infection, and alcohol use disorders, were evaluated in univariate and multivariate models. SETTING: Six US academic medical centers. PATIENTS: One thousand five hundred thirty-nine HIV-infected individuals enrolled in the CNS (Central Nervous System) HIV Anti-Retroviral Therapy Effects Research study. MAIN OUTCOME MEASURES: The presence of HIV-SN, defined by 1 or more clinical signs (diminished vibration or sharp sensation in the legs and feet; reduced ankle reflexes) in a distal, symmetrical pattern. Neuropathic pain was defined as aching, stabbing, or burning in a similar distribution. The effect on quality of life was assessed with the Medical Outcomes Study HIV Health Survey. RESULTS: We found HIV-SN in 881 participants. Of these, 38.0% reported neuropathic pain. Neuropathic pain was significantly associated with disability in daily activities, unemployment, and reduced quality of life. Risk factors for HIV-SN after adjustment were advancing age (odds ratio, 2.1 [95% confidence interval, 1.8-2.5] per 10 years), lower CD4 nadir (1.2 [1.1-1.2] per 100-cell decrease), current CART use (1.6 [1.3-2.8]), and past "D-drug" use (specific dideoxynucleoside analogue antiretrovirals) (2.0 [1.3-2.6]). Risk factors for neuropathic pain were past D-drug use and higher CD4 nadir. CONCLUSIONS: Neuropathic pain and HIV-SN remain prevalent, causing substantial disability and reduced quality of life even with successful CART. The clinical correlates of HIV-SN have changed with the evolution of treatment. These findings argue for redoubled efforts to determine HIV-SN pathogenesis and the development of symptomatic and neuroregenerative therapies.
OBJECTIVE: To provide updated estimates of the prevalence and clinical impact of human immunodeficiency virus-associated sensory neuropathy (HIV-SN) and neuropathic pain due to HIV-SN in the combination antiretroviral therapy (CART) era. DESIGN: Prospective, cross-sectional analysis. Clinical correlates for HIV-SN and neuropathic pain, including age, exposure to CART, CD4 levels, plasma viral load, hepatitis C virus infection, and alcohol use disorders, were evaluated in univariate and multivariate models. SETTING: Six US academic medical centers. PATIENTS: One thousand five hundred thirty-nine HIV-infected individuals enrolled in the CNS (Central Nervous System) HIV Anti-Retroviral Therapy Effects Research study. MAIN OUTCOME MEASURES: The presence of HIV-SN, defined by 1 or more clinical signs (diminished vibration or sharp sensation in the legs and feet; reduced ankle reflexes) in a distal, symmetrical pattern. Neuropathic pain was defined as aching, stabbing, or burning in a similar distribution. The effect on quality of life was assessed with the Medical Outcomes Study HIV Health Survey. RESULTS: We found HIV-SN in 881 participants. Of these, 38.0% reported neuropathic pain. Neuropathic pain was significantly associated with disability in daily activities, unemployment, and reduced quality of life. Risk factors for HIV-SN after adjustment were advancing age (odds ratio, 2.1 [95% confidence interval, 1.8-2.5] per 10 years), lower CD4nadir (1.2 [1.1-1.2] per 100-cell decrease), current CART use (1.6 [1.3-2.8]), and past "D-drug" use (specific dideoxynucleoside analogue antiretrovirals) (2.0 [1.3-2.6]). Risk factors for neuropathic pain were past D-drug use and higher CD4nadir. CONCLUSIONS:Neuropathic pain and HIV-SN remain prevalent, causing substantial disability and reduced quality of life even with successful CART. The clinical correlates of HIV-SN have changed with the evolution of treatment. These findings argue for redoubled efforts to determine HIV-SN pathogenesis and the development of symptomatic and neuroregenerative therapies.
Authors: Jacqueline A Pettersen; Gareth Jones; Catherine Worthington; Hartmut B Krentz; Oliver T Keppler; Ahmet Hoke; M John Gill; Christopher Power Journal: Ann Neurol Date: 2006-05 Impact factor: 10.422
Authors: B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch Journal: Science Date: 1997-07-04 Impact factor: 47.728
Authors: E A Childs; R H Lyles; O A Selnes; B Chen; E N Miller; B A Cohen; J T Becker; J Mellors; J C McArthur Journal: Neurology Date: 1999-02 Impact factor: 9.910
Authors: David M Simpson; Anna-Bettina Haidich; Giovanni Schifitto; Constantin T Yiannoutsos; Anthony P Geraci; Justin C McArthur; David A Katzenstein Journal: AIDS Date: 2002-02-15 Impact factor: 4.177
Authors: Asha R Kallianpur; Todd Hulgan; Jeffrey A Canter; Marylyn D Ritchie; Jonathan L Haines; Gregory K Robbins; Robert W Shafer; David B Clifford; David W Haas Journal: AIDS Date: 2006-07-13 Impact factor: 4.177
Authors: Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power Journal: JCI Insight Date: 2018-12-06
Authors: Jamie L Dorsey; Lisa M Mangus; Peter Hauer; Gigi J Ebenezer; Suzanne E Queen; Victoria A Laast; Robert J Adams; Joseph L Mankowski Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: Alejandro Arenas-Pinto; Jennifer Thompson; Godfrey Musoro; Hellen Musana; Abbas Lugemwa; Andrew Kambugu; Aggrey Mweemba; Dickens Atwongyeire; Margaret J Thomason; A Sarah Walker; Nicholas I Paton Journal: J Neurovirol Date: 2015-08-25 Impact factor: 2.643
Authors: Duaa Z Sakabumi; Raeanne C Moore; Bin Tang; Patrick A Delaney; John R Keltner; Ronald J Ellis Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731